Clinical Trial Search

Primary: Number of Breast Cancer Participants With Sentinel Lymph Nodes (SLN) Identification Using the CEUS Technique — 20 Participants

Primary: Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level) — 15.0; 20.0; 15.0; 15.0 minutes

Primary: Compare Concentration of Fatty Acids and Their Metabolites — 5.70; 2.95; 4.24; 3.18 mg/mL

Primary: Number of Participants With Clinical and Microbiological Response — 45; 46; 35 Participants

Primary: Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results — 147; 144; 96 Participants

Primary: Percentage of Participants With Incidence of Antidrug Antibodies (ADA) — 24.6; 18.2; 12.3; 6.1 Percentage of participants

Primary: Caregiver Perceptions of Pain Medicine Questionaire — 49.6; 49; 50.3; 50.5 units on a scale — p=.18

Primary: Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8. — -55.93; -52.64…

Primary: Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population — 12.71; 14.51…

Primary: Pharmacokinetic Parameters for the Maximum Amount of Observed Brodalumab Concentration for Treatment A and Treatment B. — 13.8; 14.8 milligrams per milliliter

Primary: Number of Validated AID Associated Product Technical Failures (PTFs) — 0; 0 PTFs

Primary: Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire — 28; 29 units on a scale

Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83

Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits

Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 0 and Cycle 1 Based on National Cancer Institute Common Terminology Criteria for…